|
Volume
21 Number 5
31 May 2019
|
|
Home
>
Publications
>
Current
Neuro-Oncology >
Volume
21, Year 2019 >
Number 5, 31 May
|
|
|
|
|
|
Gorsi HS, Malicki DM, Barsan V, Tumblin M, Yeh-Nayre L, Milburn M,
Elster JD, Crawford JR.
Nivolumab
in the Treatment of Recurrent or Refractory Pediatric Brain
Tumors: A Single Institutional Experience.
J
Pediatr Hematol Oncol. 2019 May 1, 2019;41(4):e235-e241∟.
doi: 10.1097/MPH.0000000000001339∟.
PMID: 30681550∟.
Observational
study. ˍ
|
|
|
|
Vladoiu MC, El-Hamamy I, Donovan LK, Farooq H, Holgado BL,
Sundaravadanam Y, Ramaswamy V, Hendrikse LD, Kumar S, Mack SC, Lee
JJY, Fong V, Juraschka K, Przelicki D, Michealraj A, Skowron P,
Luu B, Suzuki H, Morrissy AS, Cavalli FMG, Garzia L, Daniels C, Wu
X, Qazi MA, Singh SK, Chan JA, Marra MA, Malkin D, Dirks P,
Heisler L, Pugh T, Ng K, Notta F, Thompson EM, Kleinman CL, Joyner
AL, Jabado N, Stein L, Taylor MD.
Childhood
cerebellar tumours mirror conserved fetal transcriptional
programs.
Nature. 2019 May 1,
2019;572(7767):67-73∟.
doi: 10.1038/s41586-019-1158-7∟.
PMID: 31043743∟.
Laboratory investigation. ˍ
|
|
|
|
Guzauskas GF, Pollom EL, Stieber VW, Wang BCM, Garrison LP Jr.
Tumor treating fields and
maintenance temozolomide for newly-diagnosed glioblastoma: a
cost-effectiveness study.
J Med Econ. 2019 May 3,
2019;22(10):1006-1013∟.
doi: 10.1080/13696998.2019.1614933∟.
PMID: 31050315∟.
Observational study. ˍ
|
|
|
|
Sun Y, Sun Y, Yan K, Li Z, Xu C, Geng Y, Pan C, Chen X, Zhang L,
Xi Q.
Potent anti-tumor efficacy of
palbociclib in treatment-naïve H3.3K27M-mutant diffuse
intrinsic pontine glioma.
EBioMedicine. 2019 May
3, 2019;43:171-179∟.
doi: 10.1016/j.ebiom.2019.04.043∟.
PMID: 31060906∟.
Laboratory investigation. ˍ
|
|
|
|
Sweeney KJ, Mottolese C, Belot A, Szathmari A, Frappaz D, Lesca G,
Putoux A, Di Rocco F.
The first
case report of medulloblastoma associated with Tatton-Brown-Rahman
syndrome.
Am J Med Genet A. 2019 May 7,
2019;179(7):1357-1361∟.
doi: 10.1002/ajmg.a.61180∟.
PMID: 31066180∟.
Case report. ˍ
|
|
|
|
Jethanandani A, Gule-Monroe MK, Chen M, Johnson JM.
Extraneural
Metastases From a High-Grade Glioma (HGG) With an H3F3A G34R
Mutation.
Front Oncol. 2019 May 8, 2019;9:373∟.
doi: 10.3389/fonc.2019.00373∟.
PMID: 31139567∟.
Case report. ˍ
|
|
|
|
Jo Y, Sung J, Jeong H, Hong S, Jeong YK, Kim EH, Yoon M.
Effectiveness of a Fractionated
Therapy Scheme in Tumor Treating Fields Therapy.
Technol
Cancer Res Treat. 2019 May 9, 2019;18:1533033819845008∟.
doi: 10.1177/1533033819845008∟.
PMID: 31072204∟.
Laboratory investigation. ˍ
|
|
|
|
Tabrizi S, Yeap BY, Sherman JC, Nachtigall LB, Colvin MK, Dworkin
M, Fullerton BC, Daartz J, Royce TJ, Oh KS, Batchelor TT, Curry
WT, Loeffler JS, Shih HA.
Long-term
outcomes and late adverse effects of a prospective study on proton
radiotherapy for patients with low-grade glioma.
Radiother
Oncol. 2019 May 10, 2019;137:95-101∟.
doi: 10.1016/j.radonc.2019.04.027∟.
PMID: 31082632∟.
Interventional study. ˍ
|
|
|
|
Deopujari CE, Shah NJ, Shaikh ST, Karmarkar VS, Mohanty CB.
Endonasal endoscopic skullbase
surgery in children.
Childs Nerv Syst. 2019 May
12, 2019;35(11):2091-2098∟.
doi: 10.1007/s00381-019-04167-3∟.
PMID: 31079184∟.
Observational study. ˍ
|
|
|
|
Cuncannon M, Wong M, Jayamanne D, Guo L, Cove N, Wheeler H, Back
M.
Role of delayed salvage
bevacizumab at symptomatic progression of chemorefractory
glioblastoma.
BMC Cancer. 2019 May 14,
2019;19(1):44∟.
doi: 10.1186/s12885-019-5678-1∟.
PMID: 31088401∟.
Observational study. ˍ
|
|
|
|
Munoz-Bendix C, Rapp M, Mijderwijk HJ, von Sass C, Dibué-Adjei
M, Cornelius JF, Steiger HJ, Turowski B, Sabel M, Kamp MA.
Risk
factors for in-brain local progression in elderly patients after
resection of cerebral metastases.
Sci Rep. 2019
May 15, 2019;9(1):7431∟.
doi: 10.1038/s41598-019-43942-9∟.
PMID: 31092876∟.
Observational study. ˍ
|
|
|
*
|
Amsbaugh MJ, Yusuf M, Gaskins J, Burton E, Woo S.
The
impact of timing of adjuvant therapy on survival for patients with
glioblastoma: An analysis of the National Cancer Database.
J Clin Neurosci. 2019 May 16, 2019;66:92-99∟.
doi: 10.1016/j.jocn.2019.05.013∟.
PMID: 31104962∟.
Observational
study. ˍ
|
|
|
|
Rossi M, Ambrogi F, Gay L, Gallucci M, Conti Nibali M, Leonetti A,
Puglisi G, Sciortino T, Howells H, Riva M, Pessina F, Navarria P,
Franzese C, Simonelli M, Rudà R, Bello L.
Is
supratotal resection achievable in low-grade gliomas? Feasibility,
putative factors, safety, and functional outcome.
J
Neurosurg. 2019 May 17,
2019;132(6):1692-1705∟.
doi: 10.3171/2019.2.JNS183408∟.
PMID: 31100730∟.
Observational
study. ˍ
|
|
|
|
Gittleman
H, Ostrom QT, Stetson LC, Waite K, Hodges TR, Wright CH, Wright J,
Rubin JB, Berens ME, Lathia J, Connor JR, Kruchko C, Sloan AE,
Barnholtz-Sloan JS.
Sex
is an important prognostic factor for glioblastoma but not for
nonglioblastoma.
Neurooncol
Pract. 2019 May 18, 2019;6(6):451-462∟.
doi: 10.1093/nop/npz019∟.
PMID:
31832215∟.
Observational
study.
.ˍ
|
|
|
|
Khalil J, Qing Z, Chuanying Z, Belkacémi Y, Benjaafar N,
Mawei J.
Twenty years experience in
treating childhood medulloblastoma: Between the past and the
present.
Cancer Radiother. 2019 May 18,
2019;23(3):179-187∟.
doi: 10.1016/j.canrad.2018.05.008∟.
PMID: 31109839∟.
Observational
study. ˍ
|
|
|
|
Mitchell
D, Dey M.
Neoadjuvant
anti-PD-1 immunotherapy for recurrent glioblastoma.
Transl
Cancer Res.
2019 Dec;8(Suppl 6):S577-S579∟.
doi: 10.21037/tcr.2019.05.24∟.
PMID: 32864354∟.
Comment.
ˍ
Refers
to:
Cloughesy
TF, et al., Neoadjuvant
anti-PD-1 immunotherapy promotes a survival benefit with
intratumoral and systemic immune responses in recurrent
glioblastoma.
Nat
Med. 2019 Feb 11, 2019;25(3):477-486∟.
doi: 10.1038/s41591-018-0337-7∟.
PMID: 30742122∟.
Interventional study.
ˍ
|
|
|
|
Bouffet E.
Selumetinib in
paediatric low-grade glioma: a new era?
Lancet
Oncol. 2019 May 28, 2019;20(7):900-901∟.
doi: 10.1016/S1470-2045(19)30304-3∟.
PMID: 31151905∟.
Comment. ˍ
Refers
to: Fangusaro
J, et al, Selumetinib in paediatric patients with BRAF-aberrant or
neurofibromatosis type 1-associated recurrent, refractory, or
progressive low-grade glioma: a multicentre, phase 2 trial.
Lancet Oncol. 2019 May 28, 2019;20(7):1011-1022∟.
doi: 10.1016/S1470-2045(19)30277-3∟.
PMID: 31151904∟.
Interventional
study.
ˍ
|
|
|
|
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH,
Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack
IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P,
Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern
JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline
DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M.
Selumetinib in paediatric patients
with BRAF-aberrant or neurofibromatosis type 1-associated
recurrent, refractory, or progressive low-grade glioma: a
multicentre, phase 2 trial.
Lancet Oncol. 2019 May
28, 2019;20(7):1011-1022∟.
doi: 10.1016/S1470-2045(19)30277-3∟.
PMID: 31151904∟.
Interventional
study. ˍ
|
|
|
|
Gittleman H, Cioffi G, Chunduru P,
Molinaro AM, Berger MS, Sloan AE, Barnholtz-Sloan JS.
An
independently validated nomogram for isocitrate
dehydrogenase-wild-type glioblastoma patient survival.
Neurooncol
Adv. 2019 May 30, 2019;1(1):vdz007∟.
doi: 10.1093/noajnl/vdz007∟.
PMID:
31608326∟.
Observational
study. ˍ
|
|
|
|
|
|
|
|
|
